| Ms Roxann Linda Grey, PN M-IV | |
|
313 Oregon Dr, Xenia, OH 45385-4433 | |
| (937) 520-4268 | |
| Not Available |
| Full Name | Ms Roxann Linda Grey |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 313 Oregon Dr, Xenia, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275893539 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | 148938 (Ohio) | Secondary |
| 164W00000X | Licensed Practical Nurse | 148938 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Roxann Linda Grey, PN M-IV 313 Oregon Dr, Xenia, OH 45385-4433 Ph: (937) 520-4268 | Ms Roxann Linda Grey, PN M-IV 313 Oregon Dr, Xenia, OH 45385-4433 Ph: (937) 520-4268 |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that it is offering to sell up to 4,000,000 shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager in the offering. The co-manager in the offering is Oppenheimer & Co. Inc. Somaxon expects to grant the underwriters an option to purchase up to an additional 600,000 shares of common stock to cover overallotments of shares, if any.
A drug described by some people as a genius pill for enhancing cognitive function provided relief to a small group of Rochester breast cancer survivors who were coping with a side effect known as chemo-brain, according to a University of Rochester Medical Center study.
A new study reignites the debate regarding the therapeutic utility of convalescent plasma in treating others with the COVID-19.
High above the Earth, researchers are conducting a first-of-its-kind study to help patients with Parkinson's disease and multiple sclerosis on the planet below. The International Space Station experiment is looking for what triggers these diseases by studying how nerve and immune brain cells interact.
Halozyme Therapeutics, Inc. today announced insulin variability study results that demonstrated reduced intrasubject absorption variability for the combination of lispro, a meal time analog insulin, plus PH20 (hyaluronidase) compared to subcutaneous injection of lispro alone.
› Verified 3 days ago
Mrs. Sherri Gay Baughman, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 252 S Allison Ave, Xenia, OH 45385 Phone: 937-374-1889 | |
Kelsey Nicole Sutton, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 36 N Detroit St Ste 105, Xenia, OH 45385 Phone: 937-610-4673 | |
Latashia Rochelle Parries, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 107 E 3rd St, Xenia, OH 45385 Phone: 937-532-3884 | |
Mrs. Jody Bales, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 569 S Columbus St, Xenia, OH 45385 Phone: 937-376-3991 | |
Ms. Michelle Kay Davies, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 379 Lake St, Xenia, OH 45385 Phone: 937-232-7765 | |
Mrs. Leeanne Devivo, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 252 South Allison Avenue, Xenia, OH 45385 Phone: 937-374-1889 | |
Kimberlyn Burks, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 452 W Market St, Xenia, OH 45385 Phone: 937-376-8700 |